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Abstract
Background: The objective of this study was to validate our approach of treating primary hyperparathyroidism
using sestamibi scan directed parathyroidectomy, without routine use of intraoperative parathyroid hormone
measurements (ioPTH).
Methods: We prospectively established a protocol limiting the use of ioPTH to patients with negative or equivocal
sestamibi scans, and those who had risk factors for multi-gland disease. We then performed a retrospective review
to determine our disease control rate.
Results: 128 patients underwent sestamibi-guided parathyroidectomy without (111/128 = 87%) or with (17/128 =
13%) ioPTH. The overall disease control (eucalcemia) rate was 95%. 3/111 (3%) of patients who had surgery without
ioPTH measurements required re-exploration.
Conclusions: Selective use of ioPTH is an effective strategy. ioPTH is best reserved for patients who have
non-localizing preoperative imaging, are at risk for multi-gland disease, or require revision surgery.
Keywords: Primary hyperparathyroidism, Parathyroidectomy, Parathyroid hormone, Technetium Tc 99 m
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Background
Surgical treatment of primary hyperparathyroidism
(PHPT) has greatly evolved over the past couple of de-
cades. What was once a tedious four-gland exploration
has become a relatively short procedure directed at the
solitary abnormal gland in most instances. This para-
digm shift has been facilitated by improved preoperative
localization, usually with a Tc 99 m sestamibi scan with
or without ultrasound, and the advent of intraoperative
testing with intraoperative parathyroid hormone levels
or a gamma probe.
Intraoperative PTH monitoring (ioPTH) is by far the
most common adjunct used during surgery. Proponents
of routine ioPTH utilization site the advantage of imme-
diate confirmation of successful treatment at the time of
surgery, and the ability to detect multi- gland disease.
Multi-gland disease is purported to occur in as many as
15% of cases, which would seem to support the use of
routine testing.
The potential disadvantages of routine ioPTH utilization
are cost, added operating time, and the possibility of false
results that prompt further, unnecessary exploration.
Therefore, one can make the argument for selective
utilization. The rate of multi-gland disease is very small in
properly selected patients who have definitive localizing
scans [1–3].
We prospectively established a protocol of directed,
uni-glandular surgery based on preoperative localization,
limiting the use of ioPTH to patients with negative or
equivocal sestamibi scans, and those who had risk fac-
tors for multi-gland disease. The objective of this study
is to review our rates of ioPTH utilization and disease
control using this protocol.
Methods
The Department of Otolaryngology-Head and Neck
Surgery, University of Manitoba, established a protocol
in 2009 for selective use of ioPTH in the surgical man-
agement of PHTP. All patients would undergo preopera-
tive localization using Tc 99 m sestamibi scanning with a
view to attempting directed, uni-glandular surgery when
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possible. Ultrasound was used to strengthen preoperative
localization in selected cases. Use of ioPTH was reserved
for patients with negative or equivocal preoperative
localization, and/or risk factors for multi-glandular disease
such as known multiple endocrine neoplasia or a positive
family history.
This protocol ultimately created two groups of patients:
 Group 1: Abnormal gland localized; surgeon
anticipates probable single adenoma and plans
directed, uni-glandular surgery without ioPTH
 Group 2: Abnormal gland not localized; surgeon
anticipates increased risk for multi-gland disease or
smaller adenoma, plans for high likelihood of 4 gland
exploration, and arranges ioPTH
Frozen section pathology was used to confirm the
nature of the tissue removed intraoperatively in all pa-
tients. Three fellowship trained head and neck surgeons
performed all the operations, with the level of experi-
ence ranging from less than 5 years in practice to greater
than 15 years in practice. All procedures were performed
in tertiary care institutions with a high level of radiology
and pathology support.
We performed a retrospective chart review of patients
treated with this protocol between 2009 and 2014. The
Bannatyne Campus Research Ethics Board approved this
study. We initially included all patients undergoing sur-
gery for primary hyperparathyroidism, with or without
ioPTH monitoring. Data collected included patient
demographics, preoperative workup, operative findings,
and postsurgical outcomes.
In reviewing preoperative workup, we collected data
on preoperative calcium and parathyroid hormone
(PTH) levels, and imaging performed (sestamibi and
ultrasound). The imaging outcomes were categorized as
either positive, or negative (including weak, discordant,
or ambiguous results). Operative findings mainly focused
on the use of ioPTH, however we included documenting
bilateral and unilateral number and intraoperative path-
ology of glands removed.
Postoperatively we collected pathology reports, operative
reports, and calcium and PTH levels. Blood results were
available in the provincial electronic laboratory reporting
system, enabling biochemical follow-up often long after the
completion of surgical follow-up. A successful operation
was defined as median post operation calcium levels below
the high limit of normal. Failure was stringently defined as
ANY calcium levels above normal following surgery associ-
ated with an inappropriately elevated PTH level.
In the case of those requiring re-operation, we further
investigated these charts for qualitative information
pertaining to the surgical procedure and circumstances
surrounding the failure.
Results
140 consecutive patients underwent parathyroidectomy
over the course of this study. Twelve patients were ex-
cluded due to a variety of issues: lack of follow-up data;
confounding conditions such as systemic malignancy;
patient did not complete sestamibi scan or scan results
were not available.
This left 128 patients in the analysis, 90 females and
38 males. The mean age was 60, with a range of 20–89
years. Median follow-up was 16 months (range 1–
67 months). The mean preoperative corrected calcium
level was 2.9 +/− 0.3 mmol/l. The mean preoperative
PTH level was 183 +/− 232 ng/l.
111/128 (87%) underwent radiologically guided para-
thyroidectomy without ioPTH (Group 1), and 17/128
(13%) with ioPTH (Group 2) (Fig. 1). All patients under-
went sestamibi scanning preoperatively. 32/128 (25%)
had both sestabmibi and ultrasound. 106/111 (95%)
Group 1 patients were managed with unilateral explor-
ation. The majority (11/17 (65%)) of Group 2 patients
required bilateral exploration, as anticipated.
The overall failure rate, by very strict criteria (median
elevated calcium levels with inappropriately PTH, docu-
mented at any time postoperatively) was 6/128 (5%).
Only 3/128 required re-exploration (2%). These 3 pa-
tients were subsequently rendered eucalcemic. The other
3 cases that were classified as failures were in fact sig-
nificantly improved but had very mild, asymptomatic
Fig. 1 Patient Selection and Outcomes
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residual hypercalcemia that did not meet NIH criteria
for further surgery.
The failures were within Group 1 (no ioPTH) . Thus
the failure rate for sestamibi-guided surgery without
ioPTH was 6/111 (5%), and the re-exploration rate was
3/111 (3%).
Discussion
There is a good body of literature supporting the use of
ioPTH monitoring. The addition of ioPTH has facilitated
a transition to radiologically-guided, minimally invasive
parathyroid surgery. This has improved surgical outcomes
relative to traditional four-gland exploration both by de-
creasing operative times, hospital costs, and avoiding un-
necessary risk to the patient [4–7]. Despite this, routine
use of ioPTH for primary hyperparathyroidism surgery
may be unnecessary in appropriately selected patients.
Proponents of routine use of ioPTH quote multi-gland
disease figures upwards of 15% [8–11]. However, the rate
of multi-gland disease in patients that have no risk fac-
tors, and a positive preoperative localization is likely far
less than that. The low rate of failure after uni-glandular
surgery in our study and others [1, 3, 12] would support
the notion that the rate of multi-gland disease in prop-
erly selected patients is 5% or less.
The authors acknowledge the importance of analyzing
cost-effectiveness in any debate regarding one treatment
vs another; in this case routine use vs selective use of
ioPTH in parathyroidectomy for primary hyperparathyr-
oidism. However, the retrospective nature of this study
precludes any sophisticated analysis of cost differential
and is beyond the design of the project. Nevertheless, we
feel that a basic comment on a clinical impression that
is apparent in many centers, and that provides the im-
petus for a movement away from routine use of ioPTH
is warranted: Waiting 10–20 min to draw blood and the
subsequent wait for a ioPTH assay adds clinically signifi-
cant amounts of time to surgery when compared to ses-
timibi directed surgery with frozen section confirmation
that an enlarged parathyroid has been removed.
The first 10–20 min after adenoma excision in either
case represents wound closure and simultaneous waiting
for frozen section (non-ioPTH case) or time to pass before
drawing the ioPTH bloodwork (ioPTH protocol). The
subsequent wait for an ioPTH assay often adds over 15–
30 min to the case in our institution. Therefore, one can
roughly calculate that 25–50 h of operating time would be
consumed for every 100 cases, awaiting ioPTH results.
Considering this would have been for theoretically redu-
cing our reoperation rate from 3 patients per hundred
down to 0–2 per hundred, this hardly seems worthwhile.
Even if prospectively collected randomized cost-
effectiveness data pertaining to the extended time and
cost for one protocol vs another is available, one must
consider many other issues that are much more difficult
to factor into the analysis: What are the effects of freeing
up 25–50 h of operating on patients OUTSIDE the
study? What is the cost of unnecessarily extended opera-
tions based on misleading results in the ioPTH group?
What is the cost of reoperation of patients who have
persistent disease in both groups? What is the QALY
impact of complications from over-exploration in the
ioPTH group? What is the QALY impact of uncon-
trolled disease in both groups?
We, like many centers, rely on sestamibi with or with-
out ultrasound for accurate localization. Some studies
have shown up to 97–100% sensitivity and 100% specifi-
city of sestamibi scans [13–15]. Factors shown to decrease
sensitivity or result in negative scans are multi-gland dis-
ease, small hypersecreting glands, lower levels of serum
calcium, and body mass index and gland size [16–19].
These factors can easily be determined clinically, allowing
confident selection of patients for ioPTH.
Our results are consistent with similar published studies
investigating image guided parathyroidectomy without
ioPTH, ranging from success rates of 92–100% [20–22].
Comparatively, our local failure rate was 5% with a reoper-
ation rate of 3%. Jacobson et al. [1] published a similar
retrospective analysis in 2002, reporting eucalcemia in
97% with persistent hypercalcemia in 3 patients (3%), one
of which required reoperation. They note similar inclusion
criteria as in our study. In another more recent study in
2015, Mownah et al. cite a 97% cure rate without ioPTH
in patients with concordant preoperative sestamibi and
ultrasound [2]. In this instance on-table ultrasound was
used. In contrast, a review published in 2015, stresses the
need for ioPTH monitoring to avoid surgical failure [23],
however, their success rates were 94.9% in patients with-
out ioPTH and 100% with ioPTH. Failure of imaging to
localize the adenoma or discordance between sestamibi
and ultrasound imaging was used to determine use of
ioPTH, again similar to our protocol. While the success
rate in this study is an impressive 100%, success rates in
the non-ioPTH group still fall within expected ranges
cited above.
Proper patient selection for ioPTH does not guarantee a
successful outcome, as even minimally invasive surgery
with ioPTH monitoring can lead to failures. One in fifteen
patients in our study remained persistently hypercalcemic
with a negative follow-up sestamibi. Ultimately, the gold
standard has been bilateral neck exploration by an experi-
enced head and neck surgeon. In 2004 Siperstein et al.
found additional pathology in the contralateral neck in
15% of patients with ioPTH monitoring and concordant
sestamibi and ultrasound imaging [24]. Surgeon experi-
ence led to bilateral exploration in patients with two ab-
normal appearing glands. Later, a review of the usefulness
of ioPTH in 2011 concluded that the test may only be as
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good as the surgeon, requiring proper interpretation con-
sidering possible multi-gland disease and using appropri-
ate ioPTH criteria [25].
With such conflicting opinions, it is interesting that
Sitger-Serra et al. note that using technical advances,
such as ioPTH may be more appealing to less experi-
enced surgeons, as it may serve as a fail-safe or compen-
sate for anatomical intricacies of parathyroid surgery
[26]. It is obviously important for centers to consider
local expertise and the availability and cost of timely
ioPTH testing when developing local strategies for min-
imizing the cost and time of parathyroidectomy, and the
need for re-exploration.
One might be tempted to conclude that our zero-
failure rate in the non-localizing group, in which ioPTH
was used, contradicts our support for exploration with-
out ioPTH. However, it is important to note that this is
a small group of 17 patients. Obviously, with an ad-
equate sample size the failure rate will exceed zero. As
well, these 17 patients were managed not only with the
addition of ioPTH, but also frequent bilateral exploration,
additional imaging, and additional OR time. Therefore,
one cannot conclude that it is the addition of ioPTH that
is the sole factor that may have improved outcome in this
group. To use all of these additional measures in every
sestimibi localized case would go entirely against the rec-
ognized success and savings of directed exploration, and
potentially add risk in terms of unnecessarily extended
exploration.
Philosophically, one must accept the fact that there
will be a very small percent of cases that may have to re-
turn to the operating room for further exploration no
matter how much preoperative testing, intraoperative test-
ing, and exploration is performed. If one really wants to
reduce the risk of needing re-exploration as much as pos-
sible, one would have to add ioPTH and other forms of
imaging to routine four-gland exploration which will re-
sult in an unreasonable increase in cost, OR time and risk.
Conclusions
Selective use of ioPTH is an effective strategy. Intraoper-
ative PTH monitoring is best reserved for patients who
have non-localizing preoperative imaging, are at risk for
multi-gland disease, or require revision surgery.
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